- Goldman is out with an update on IMS data for some of Amgen's (AMGN) key drugs.
- "Sales are tracking slightly ahead of our estimates," analyst Terence Flynn says, adding that "Kyprolis, Epogen and Prolia are particularly strong, while Enbrel and Neulasta are tracking in-line and Aranesp is slightly below."
- Flynn sees Q4 Kyprolis sales coming in at $76M versus consensus of $71M.
- AMGN reiterated at Buy.
- Price target is $130.
Goldman reiterates bullish rating on Amgen, sees Kyprolis sales ahead of consensus
Nov 29 2013, 11:27 ET